The choice of EGFR as a target was due to the high expression of this receptor in a primary glioblastoma (observed in 60% of patients, EGFRvIII mutation in 50% of patients) (12), as well as the known negative effect of this biomarker on the prognosis of the disease. Here, EGFR is linked to glioblastoma.